The ongoing product liability issues continue for Glaxo SmithKline and their antidepressent drug Paxil.

Turns out that they suppressed information regarding suicide rates among clinical test subjects. They also failed to report stimulatory effects that could potentially make Paxil users hyperactive or even aggresive.